The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

SHLP6

SHLP6 · Small Humanin-Like Peptide 6

C
Animal replicated
Research chemicalMitochondrial-Derived PeptideHumanin-Like PeptideApoptotic Peptide
RouteInjectableGray-market only
C
Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance
What it is
Small Humanin-Like Peptide 6 — The Apoptotic MDP — Mitochondrial-Derived Peptide, Humanin-Like Peptide, Apoptotic Peptide.
Why people use it
Apoptosis Induction · Cancer Cell-Specific Selectivity · Neuroprotection in Oxidative Stress Models · Cellular Quality Control and Cancer Surveillance
What the evidence supports
SHLP6 has the thinnest evidence base of any compound in this reference that has active community use. Its primary evidence is a 2016 cell culture finding in two cell lines, a 2025 zebrafish study, and 2025 in silico modeling. The positive natural selection analysis from an independent group provides meaningful indirect evidence of biological importance. The entire 'beneficial' narrative for SHLP6 rests on a hypothesis — the dual-function cancer surveillance hypothesis — that has not been directly tested. Community users drawn to SHLP6 for its potential pro-apoptotic/cancer-surveillance properties are self-experimenting with a compound whose mechanism in living humans is essentially uncharacterized.
If you only read one thing

SHLP6 is the only pro-apoptotic member of the SHLP family. This makes it simultaneously the most potentially dangerous and the most therapeutically interesting. The danger: pro-apoptotic compounds in the wrong cellular context — whether in healthy tissue, in the context of another stress, or in combination with other compounds — could cause inappropriate cell death. The therapeutic interest: if SHLP6 specifically kills damaged, aged, or malignantly transformed cells while sparing healthy ones, it represents a natural cancer surveillance mechanism of mitochondrial origin. The dual-function hypothesis (Frontiers 2025) — pro-apoptotic in cancer cells, cytoprotective in normal cells — is the most important mechanistic claim in SHLP6's young research history. It has not been rigorously demonstrated in animal models or any human context. The entire SHLP6 chapter must be read with this uncertainty front and center.

Check interactions →
Published literature
0human trials0human studies0animal0in vitro
Evidence reality check
Human evidence
No human studies
0 observational; RCT evidence not present in corpus.
Preclinical base
0 lab signals
0 animal; 0 in-vitro/mechanistic.
Evidence snapshot
SHLP6 has the thinnest evidence base of any compound in this reference that has active community use. Its primary evidence is a 2016 cell culture finding in two cell lines, a 2025 zebrafish study, and 2025 in silico modeling. The positive natural selection analysis from an independent group provides meaningful indirect evidence of biological importance. The entire 'beneficial' narrative for SHLP6 rests on a hypothesis — the dual-function cancer surveillance hypothesis — that has not been directly tested. Community users drawn to SHLP6 for its potential pro-apoptotic/cancer-surveillance properties are self-experimenting with a compound whose mechanism in living humans is essentially uncharacterized.
From the chapter quick-reference block.
Indication map
Supported / plausible / speculative / avoid
Speculative
Apoptosis Induction · Cancer Cell-Specific Selectivity · Neuroprotection in Oxidative Stress Models · Cellular Quality Control and Cancer Surveillance
SHLP6 has the thinnest evidence base of any compound in this reference that has active community use. Its primary evidence is a 2016 cell culture finding in two cell lines, a 2025 zebrafish study, and 2025 in silico modeling. The positive natural selection analysis from an independent group provides meaningful indirect evidence of biological importance. The entire 'beneficial' narrative for SHLP6 rests on a hypothesis — the dual-function cancer surveillance hypothesis — that has not been directly tested. Community users drawn to SHLP6 for its potential pro-apoptotic/cancer-surveillance properties are self-experimenting with a compound whose mechanism in living humans is essentially uncharacterized.

SHLP6 is the compound in this reference that makes you ask the deepest biological question: why would an organism evolve to encode a cell-killing signal in the genome of the organelle that produces life's energy? The answer to that question may be more important than any individual therapeutic application.

The central tension resolved: SHLP6 is the outlier in the MDP family. Every other MDP in this reference protects cells from death. SHLP6 causes it. The pro-apoptotic activity is documented in cell culture (Cobb 2016); the evolutionary importance is supported by independent natural selection analysis (Barker & Bhatt 2023); a neuroprotective dimension in an oxidative stress model has been independently documented (Frontiers 2025); and a dual-function hypothesis — pro-apoptotic in cancer cells, cytoprotective in normal cells — provides a coherent framework for why this compound exists and what it does. That hypothesis is not confirmed. No experiment has directly demonstrated SHLP6 selectively killing cancer cells while protecting normal ones in a controlled comparison. The community using SHLP6 is doing so based on the most preliminary evidence of any compound covered here.

The strongest argument for SHLP6's importance as a research area: if mitochondria have evolved to encode a peptide that kills cells, and that peptide shows positive natural selection across vertebrate evolution, and it appears to have context-dependent effects that spare normal cells, then SHLP6 may represent a fundamental biological mechanism — a mitochondria-level cancer surveillance system — that has been hiding in the organelle genome for millions of years. Understanding it could be important for cancer biology, aging research, and cellular quality control science regardless of whether it ever becomes a therapeutic compound.

The strongest argument for caution in community use: SHLP6 is a pro-apoptotic compound with no confirmed cellular selectivity, no pharmacokinetic data in any species, no validated human dose, no human correlative data, no animal model efficacy data beyond zebrafish, and an active malignancy context that cannot be responsibly characterized. It is the most frontier-level self-experiment in this reference.

Categories
Cognition & MoodLongevity & Anti-agingMitochondrial & Energy
Properties
Active malignancy: hard stopNot injectable
Evidence
CAnimal replicated
The Defining Difference
SHLP6 is the only member of the SHLP family — and the only MDP in this reference — that induces apoptosis. Every other SHLP (especially SHLP2 and SHLP3), Humanin, and MOTS-c are cytoprotective: they protect cells from death. SHLP6 kills cells. In multiple cell lines tested in the original 2016 characterization (Cobb et al., Aging), SHLP6 treatment caused significant cell death through apoptotic pathways.
The Dual Function Hypothesis
Recent literature (Frontiers in Molecular Neuroscience, 2025) frames SHLP6 as having dual functionality: pro-apoptotic in cancer cells and cytoprotective in normal cells. This context-dependent activity — if confirmed — would position SHLP6 as a natural cancer surveillance peptide encoded in mitochondrial DNA, capable of distinguishing between healthy cells and those that should be eliminated.
Why Mitochondria Would Encode a Cell Killer
The question the basic biology demands: why would mitochondria encode a peptide that triggers the death of the cell they live in? The probable answer: cellular quality control. Aged, damaged, or pre-cancerous cells may express SHLP6 as part of a mitochondrial stress response, triggering apoptosis of cells that have accumulated too much damage to be worth preserving. This would be an elegant built-in cancer surveillance mechanism encoded at the organelle level.
Natural Selection Evidence
Barker & Bhatt (PNAS, 2023) performed independent evolutionary analysis of MDP coding sequences across vertebrates. SHLP6 and Humanin both show signatures of positive natural selection — meaning evolutionary pressure has specifically maintained their sequences over millions of years of vertebrate evolution. This is strong indirect evidence that SHLP6 performs a biologically important function, even if that function is not yet fully characterized.
Current Evidence Base
Cobb et al. (Aging, 2016): pro-apoptotic in multiple cell lines. Frontiers 2025: NLRP3 and Cav1 modulation, copper-induced neurodegeneration protection. ScienceDirect 2025: in silico molecular docking showing interactions with Caspase 8, Bcl-2, Bax, DRP1, SIRT1 — providing mechanistic plausibility for both pro-apoptotic and neuroprotective effects. All evidence is cell culture or in silico. No animal models. No human data.
Community Use
Extremely small community — likely the smallest of any compound in this reference. Users are primarily researchers and advanced biohackers fascinated by the pro-apoptotic mechanism, sometimes combining SHLP6 with senolytics (FOXO4-DRI) or anti-cancer protocols. Community dose: 0.5-1 mg SubQ, weekly. No validated dose.
Active Malignancy Consideration
The pro-apoptotic mechanism is the reason some community users are interested in SHLP6 for cancer-adjacent applications. This creates an unusual situation: unlike every other compound in this reference where active malignancy is a contraindication (due to pro-survival mechanisms), SHLP6's pro-apoptotic mechanism could theoretically be beneficial in cancer contexts. However, the dual-function hypothesis (pro-apoptotic in cancer cells, cytoprotective in normal cells) requires confirmation. Without that confirmation, SHLP6 near cancer is a two-edged question that cannot be resolved by available evidence.
FDA / Regulatory
Not FDA-approved. Not PCAC-reviewed. Research chemical only. Not a controlled substance.
WADA
Not listed on the 2026 WADA Prohibited List. Not a performance-enhancing compound by any characterized mechanism. CohBar Inc. Same commercial relationship as other MDPs: Pinchas Cohen (primary researcher) is consultant and stockholder in CohBar Inc. Disclosed in MDP publications. Note when evaluating Cohen group research.
Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Alternatives

Compare nearby options

Browse this classCompare 4 side by side →
Humanin
C
Same class · Mitochondrial-Derived Peptide

Found in Surviving Brain Cells of an Alzheimer's Patient. Encoded in Mitochondrial DNA. Higher in Centenarians' Children. Inversely Correlated With IGF-1. The GH Axis the Community Raises for Anti-Aging Suppresses It.

SHLP2
C
Same class · Mitochondrial-Derived Peptide

The Metabolically Active Member of a Six-Peptide Family From the Same Mitochondrial Gene as Humanin. A Receptor Has Been Found. An Obesity Protection Mechanism Has Been Identified. Lower Levels Are Associated With Prostate Cancer Risk. No Human Trial Has Been Run.

MOTS-c
C
Same class · Mitochondrial-Derived Peptide

Mitochondrial-derived peptide studied for AMPK signaling, metabolic stress resilience, and exercise-mimetic pathways.

Check interactions